GlucoSense is initially available for wetted autoclave workflows, supporting glass and benchtop bioreactors widely used in R&D and early process development. Hamilton is actively advancing the next phase of product development, and a SIP- and steam-compatible version for steel bioreactors — suitable for clinical and commercial manufacturing — is planned for release by the end of 2026.

“Bioprocessing teams have been asking for a simple, reliable way to measure glucose in situ for years,” said Giovanni Campolongo, Senior Market Segment Manager at Hamilton. “With GlucoSense, we’re giving customers real-time visibility into one of the most critical parameters in mammalian cell culture without the complexity, drift, or calibration burden that has limited previous technologies. And we’ve designed the product roadmap to support every step of the development lifecycle, from R&D to GMP manufacturing.”